At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine.

Nipah virus, which circulates in fruit bats and other animals primarily in Asia and the South Pacific, causes severe neurological respiratory disease in humans and leads to death in 40%-75% of cases. The virus is endemic in Bangladesh and India, where outbreaks have occurred nearly annually since 2001.

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans. Developed by researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, the world-first study found mice treated with the antiviral compound were protected from long-term brain and lung dysfunction, which are key symptoms of long COVID.

Orexo AB has announced promising in vivo proof-of-concept data for a powder-based intranasal vaccine candidate based on Abera Bioscience AB’s BERA vaccine platform and formulated with Orexo’s Amorphox technology.

Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because of its high incidence in North America and Europe and its increasing presence due to the impacts of climate change on vector distribution. Novel, effective vaccines to prevent the disease are, therefore, urgently needed.

Sepsis-induced coagulopathy (SIC) is a complication of sepsis tied to high mortality in patients. Anticoagulation using a coagulation factor IIa and Xa dual inhibitor might have the potential to improve the treatment of this severe condition.